Showing results (161-170 of 178) with videos related to
Sort By:
Pageof 18
Bioconjugate Chemistry|February 27, 2018
Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker ModificationDian Su, Katherine R Kozak, Jack Sadowsky, et al.International Journal of Radiation Oncology, Biology, Physics|November 20, 2013
Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summaryPaul E Wallner, Mitchell S Anscher, Christopher A Barker, et al.Oncology Research and Treatment|August 27, 2018
EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on ArtifactsElena D Lavdovskaia, Aglaya G Iyevleva, Anna P Sokolenko, et al.Molecular Cancer Therapeutics|April 20, 2013
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphomaDongwei Li, Kirsten Achilles Poon, Shang-Fan Yu, et al.Bioconjugate Chemistry|June 22, 2017
Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug ConjugatesJack D Sadowsky, Thomas H Pillow, Jinhua Chen, et al.Molecular Cancer Therapeutics|January 7, 2012
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer modelCinthia V Pastuskovas, Eduardo E Mundo, Simon P Williams, et al.Vestnik Khirurgii Imeni I. I. Grekova|August 4, 2007
[The first successful bilateral lung transplantation in Russia]P K Iablonskiĭ, A G Chuchalin, Zh Massard, et al.Mabs|December 31, 2020
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor responseJosefa Dela Cruz Chuh, MaryAnn Go, Yvonne Chen, et al.Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.Cancer Immunology, Immunotherapy : CII|August 7, 2024
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunityAurelie Herault, Judy Mak, Josefa de la Cruz-Chuh, et al.Pageof 18